Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (26.03.2026)
HOCH Abgang Schlüsselpersonen (26.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 26.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | herein by reference under this Item 5.01. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; |
| 10.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
Unternehmen & Branche
| Name | Viskase Holdings, Inc. |
|---|---|
| Ticker | ENZN |
| CIK | 0000727510 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 4,9 Mio. USD |
| Beta | 0,08 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -3,409,000 | -0.07 | 42,813,000 | -2,525,000 | |
| 2025-09-30 | 10-Q | -824,000 | -0.02 | 43,693,000 | -923,000 | |
| 2025-06-30 | 10-Q | -990,000 | -0.02 | 44,780,000 | 432,000 | |
| 2025-03-31 | 10-Q | -524,000 | -0.01 | 45,521,000 | 1,953,000 | |
| 2024-12-31 | 10-K | 26,000 | 778,000 | -0.01 | 47,169,000 | 3,008,000 |
| 2024-09-30 | 10-Q | 26,000 | 254,000 | 0.00 | 47,276,000 | 2,762,000 |
| 2024-06-30 | 10-Q | 26,000 | 276,000 | 0.00 | 46,994,000 | 3,039,000 |
| 2024-03-31 | 10-Q | 0 | 320,000 | 0.00 | 46,829,000 | 3,294,000 |
| 2023-12-31 | 10-K | 1,373,000 | 0.00 | 47,702,000 | -3,505,000 | |
| 2023-09-30 | 10-Q | 0 | 321,000 | 0.00 | 46,997,000 | 2,515,000 |
| 2023-06-30 | 10-Q | 0 | 183,000 | 0.00 | 46,672,000 | 2,725,000 |
| 2023-03-31 | 10-Q | 0 | 197,000 | 0.00 | 46,495,000 | 3,073,000 |
| 2022-12-31 | 10-K | 26,000 | -186,000 | -0.02 | 47,589,000 | 3,407,000 |
| 2022-09-30 | 10-Q | 0 | -15,000 | -0.01 | 47,257,000 | 2,756,000 |
| 2022-06-30 | 10-Q | 0 | -213,000 | -0.01 | 47,224,000 | 3,302,000 |
| 2022-03-31 | 10-Q | 0 | -291,000 | -0.01 | 47,470,000 | 4,046,000 |
| 2021-12-31 | 10-K | 701,000 | -469,000 | -0.03 | 47,754,000 | 4,868,000 |
| 2021-09-30 | 10-Q | 0 | -226,000 | -0.01 | 47,963,000 | 5,608,000 |
| 2021-06-30 | 10-Q | 291,000 | -19,000 | -0.01 | 48,246,000 | 6,340,000 |
| 2021-03-31 | 10-Q | 381,000 | 11,000 | -0.01 | 48,292,000 | 6,865,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.